Loading...
•
Jun 30
ZimVie Q2 2025 Earnings Report
ZimVie reported its second quarter 2025 financial results, showing a slight decrease in net sales but an improvement in net loss and adjusted EBITDA compared to the previous year.
Key Takeaways
ZimVie reported net sales of $116.7 million for the second quarter of 2025, a slight decrease of 0.1% year-over-year. The company significantly improved its net loss, reducing it to $(3.8) million from $(9.6) million in the prior year, and achieved an adjusted diluted EPS of $0.26. Adjusted EBITDA also saw an increase to $17.5 million, reflecting improved operational efficiency.
Net sales for Q2 2025 were $116.7 million, a marginal decrease of 0.1% compared to Q2 2024.
Net loss from continuing operations improved significantly to $(3.8) million in Q2 2025, from $(9.6) million in Q2 2024.
Adjusted EBITDA from continuing operations increased to $17.5 million, with an adjusted EBITDA margin of 15.0%.
GAAP diluted EPS from continuing operations was $(0.14), while adjusted diluted EPS was $0.26 for the quarter.
ZimVie
ZimVie
ZimVie Revenue by Geographic Location
Revenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
ZimVie is withdrawing its fiscal 2025 guidance due to a pending acquisition by ARCHIMED, which is expected to close by year-end 2025.
Positive Outlook
- Definitive agreement to be acquired by ARCHIMED for $19.00 in cash per share.
- Transaction expected to close by year-end 2025.
- Upon completion, ZimVie will become a privately held company.
- Shares of ZimVie common stock will no longer be publicly traded on NASDAQ.
- The acquisition provides a clear path forward for the company.
Challenges Ahead
- Withdrawal of fiscal 2025 guidance means no future financial outlook from the company.
- No conference call will be hosted for the second quarter due to the pending transaction.
- Reliance on previous financial guidance is no longer advised.
- Transaction is subject to customary closing conditions, including stockholder and regulatory approvals.
- Potential for the transaction to not be completed in a timely manner or at all.